Advertisement
Case report| Volume 20, ISSUE 7, P795-798, July 1985

Persistent drug-induced parkinsonism

  • Thomas A. Aronson
    Correspondence
    Address reprint requests to Dr. Thomas A. Aronson, State University of New York at Stony Brook, Health Sciences Center, T-10, Stony Brook, NY 11794.
    Affiliations
    State University of New York at Stony Brook, Health Sciences Center, Stony Brook, NY, USA
    Search for articles by this author
DOI:https://doi.org/10.1016/0006-3223(85)90160-X
Persistent drug-induced parkinsonism
Previous ArticleFlu-like illness after discontinuance of imipramine
Next ArticlePlasma catecholamines and ECT
      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Ayd Jr, F.J.
        A survey of drug induced extra pyramidal reactions.
        JAMA. 1961; 175: 1054-1060
        • Ayd Jr, F.J.
        Haloperidol: Fifteen years of clinical experience.
        Dis Nerv Syst. 1972; 33: 459-469
        • Berkmeyer W.
        • et al.
        Deprenyl prolongs life of patients with Parkinson's disease.
        Mod Probl Pharmacopsychiatry. 1983; 19: 170-176
        • Demars J.P.C.A.
        Neuromuscular effects of long term phenothiazine medication, ECT, and leucotomy.
        J Nerv Ment Dis. 1966; 143: 73-79
        • Fleming P.
        • Makar H.
        • Hunter K.R.
        Levodopa in drug-induced extrapyramidal disorders.
        Lancet. 1970; ii: 1186
        • Freyhan F.A.
        Psychomotility and parkinsonism in treatment with neuroleptic drugs.
        Arch Neurol Psychiatry. 1957; 76: 56
        • Heikerita R.E.
        • et al.
        Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
        Nature. 1984; 311: 467-469
        • Marsden C.D.
        • Tarsy D.
        • Baldessarini R.L.
        Movement disorders in psychotic patients.
        in: Benson D.F. Blumer D. Psychiatric Aspects of Neurologic Disease. Grune and Stratton, Orlando, FL1975: 219-266
        • Rivera V.M.
        • Keichian A.H.
        • Oliver R.E.
        Persistent parkinsonism following neuroleptanalgesia.
        Anesthesiology. 1975; 42: 635-637
        • Schiele B.C.
        • et al.
        Comparison of low dose and high dose procedures in chlorpromazine therapy.
        Psychiat Q. 1959; 33: 252-259
        • Schmid W.R.
        • Jarcho L.W.
        Persistent dyskinesias following phenothiazine treatment.
        Arch Neurol. 1966; 14: 369-377
        • Schwab R.S.
        • England Jr, A.C.
        Parkinson syndromes due to various specific causes.
        Handbook of Clinical Neurology, Vol 6, Diseases of the Basal Ganglia. 1968; : 227-247

      Article info

      Publication history

      Received in revised form: January 15, 1985
      Received: November 20, 1984

      Identification

      DOI: https://doi.org/10.1016/0006-3223(85)90160-X

      Copyright

      © 1985 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX